Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line

Xu Feng Qi, Dong Heui Kim, Yang Suk Yoon, Jian Hong Li, Dan Jin, Yung Chien Teng, Soo-Ki Kim, Kyu Jae Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background and purpose: The macrophage-derived chemokine (MDC/CCL22) is a prototypic Th2-type chemokine intimately involved in Th2-skewed allergic diseases, such as atopic dermatitis and asthma. The statins (3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors) have been demonstrated to relieve allergic inflammation. However, the immunological effects and mechanisms of statins against atopic dermatitis remain unknown, at least in vitro. This study aimed to define how different statins affect MDC expression in HaCaT cells, a human keratinocyte cell line. Experimental approach: To measure the effects of statins on MDC expression in HaCaT cells, we used a cell viability assay, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay and Western blotting analyses. Key results: Fluvastatin, but not atorvastatin or simvastatin, inhibited MDC expression induced by interferon (IFN)-γ and NF-κB activation. A NF-κB inhibitor, but not a STAT1 inhibitor, suppressed MDC expression in HaCaT cells. Further, inhibition of p38 mitogen-activated protein kinases (MAPKs) significantly suppressed IFN-γ-induced MDC expression and NF-κB activation. Interestingly, fluvastatin suppressed IFN-γ-induced NF-κB activation in parallel with p38 MAPK phosphorylation. Conclusions and implications: These results indicate that fluvastatin inhibited expression of the CC chemokine MDC induced by IFN-γ in HaCaT cells, by inhibiting NF-κB activation via the p38 MAPK pathway. This blockade of a Th2 chemokine by fluvastatin may suppress the infiltration of Th2 cells into skin lesions and lessen the skin inflammation seen in atopic dermatitis, suggesting a potential therapeutic use of fluvastatin for this condition.

Original languageEnglish
Pages (from-to)1441-1450
Number of pages10
JournalBritish Journal of Pharmacology
Volume157
Issue number8
DOIs
Publication statusPublished - 2009 Oct 29

Fingerprint

fluvastatin
Chemokine CCL22
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Keratinocytes
Interferons
p38 Mitogen-Activated Protein Kinases
Cell Line
Atopic Dermatitis
Chemokines
Inflammation
CC Chemokines
Th2 Cells
Skin
Simvastatin
Therapeutic Uses
Reverse Transcription
Cell Survival
Oxidoreductases
Asthma
Western Blotting

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Qi, Xu Feng ; Kim, Dong Heui ; Yoon, Yang Suk ; Li, Jian Hong ; Jin, Dan ; Teng, Yung Chien ; Kim, Soo-Ki ; Lee, Kyu Jae. / Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line. In: British Journal of Pharmacology. 2009 ; Vol. 157, No. 8. pp. 1441-1450.
@article{013b39b1cf614146bea9e7fdc8aeb5aa,
title = "Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line",
abstract = "Background and purpose: The macrophage-derived chemokine (MDC/CCL22) is a prototypic Th2-type chemokine intimately involved in Th2-skewed allergic diseases, such as atopic dermatitis and asthma. The statins (3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors) have been demonstrated to relieve allergic inflammation. However, the immunological effects and mechanisms of statins against atopic dermatitis remain unknown, at least in vitro. This study aimed to define how different statins affect MDC expression in HaCaT cells, a human keratinocyte cell line. Experimental approach: To measure the effects of statins on MDC expression in HaCaT cells, we used a cell viability assay, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay and Western blotting analyses. Key results: Fluvastatin, but not atorvastatin or simvastatin, inhibited MDC expression induced by interferon (IFN)-γ and NF-κB activation. A NF-κB inhibitor, but not a STAT1 inhibitor, suppressed MDC expression in HaCaT cells. Further, inhibition of p38 mitogen-activated protein kinases (MAPKs) significantly suppressed IFN-γ-induced MDC expression and NF-κB activation. Interestingly, fluvastatin suppressed IFN-γ-induced NF-κB activation in parallel with p38 MAPK phosphorylation. Conclusions and implications: These results indicate that fluvastatin inhibited expression of the CC chemokine MDC induced by IFN-γ in HaCaT cells, by inhibiting NF-κB activation via the p38 MAPK pathway. This blockade of a Th2 chemokine by fluvastatin may suppress the infiltration of Th2 cells into skin lesions and lessen the skin inflammation seen in atopic dermatitis, suggesting a potential therapeutic use of fluvastatin for this condition.",
author = "Qi, {Xu Feng} and Kim, {Dong Heui} and Yoon, {Yang Suk} and Li, {Jian Hong} and Dan Jin and Teng, {Yung Chien} and Soo-Ki Kim and Lee, {Kyu Jae}",
year = "2009",
month = "10",
day = "29",
doi = "10.1111/j.1476-5381.2009.00311.x",
language = "English",
volume = "157",
pages = "1441--1450",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line. / Qi, Xu Feng; Kim, Dong Heui; Yoon, Yang Suk; Li, Jian Hong; Jin, Dan; Teng, Yung Chien; Kim, Soo-Ki; Lee, Kyu Jae.

In: British Journal of Pharmacology, Vol. 157, No. 8, 29.10.2009, p. 1441-1450.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-g in HaCaT cells, a human keratinocyte cell line

AU - Qi, Xu Feng

AU - Kim, Dong Heui

AU - Yoon, Yang Suk

AU - Li, Jian Hong

AU - Jin, Dan

AU - Teng, Yung Chien

AU - Kim, Soo-Ki

AU - Lee, Kyu Jae

PY - 2009/10/29

Y1 - 2009/10/29

N2 - Background and purpose: The macrophage-derived chemokine (MDC/CCL22) is a prototypic Th2-type chemokine intimately involved in Th2-skewed allergic diseases, such as atopic dermatitis and asthma. The statins (3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors) have been demonstrated to relieve allergic inflammation. However, the immunological effects and mechanisms of statins against atopic dermatitis remain unknown, at least in vitro. This study aimed to define how different statins affect MDC expression in HaCaT cells, a human keratinocyte cell line. Experimental approach: To measure the effects of statins on MDC expression in HaCaT cells, we used a cell viability assay, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay and Western blotting analyses. Key results: Fluvastatin, but not atorvastatin or simvastatin, inhibited MDC expression induced by interferon (IFN)-γ and NF-κB activation. A NF-κB inhibitor, but not a STAT1 inhibitor, suppressed MDC expression in HaCaT cells. Further, inhibition of p38 mitogen-activated protein kinases (MAPKs) significantly suppressed IFN-γ-induced MDC expression and NF-κB activation. Interestingly, fluvastatin suppressed IFN-γ-induced NF-κB activation in parallel with p38 MAPK phosphorylation. Conclusions and implications: These results indicate that fluvastatin inhibited expression of the CC chemokine MDC induced by IFN-γ in HaCaT cells, by inhibiting NF-κB activation via the p38 MAPK pathway. This blockade of a Th2 chemokine by fluvastatin may suppress the infiltration of Th2 cells into skin lesions and lessen the skin inflammation seen in atopic dermatitis, suggesting a potential therapeutic use of fluvastatin for this condition.

AB - Background and purpose: The macrophage-derived chemokine (MDC/CCL22) is a prototypic Th2-type chemokine intimately involved in Th2-skewed allergic diseases, such as atopic dermatitis and asthma. The statins (3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors) have been demonstrated to relieve allergic inflammation. However, the immunological effects and mechanisms of statins against atopic dermatitis remain unknown, at least in vitro. This study aimed to define how different statins affect MDC expression in HaCaT cells, a human keratinocyte cell line. Experimental approach: To measure the effects of statins on MDC expression in HaCaT cells, we used a cell viability assay, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay and Western blotting analyses. Key results: Fluvastatin, but not atorvastatin or simvastatin, inhibited MDC expression induced by interferon (IFN)-γ and NF-κB activation. A NF-κB inhibitor, but not a STAT1 inhibitor, suppressed MDC expression in HaCaT cells. Further, inhibition of p38 mitogen-activated protein kinases (MAPKs) significantly suppressed IFN-γ-induced MDC expression and NF-κB activation. Interestingly, fluvastatin suppressed IFN-γ-induced NF-κB activation in parallel with p38 MAPK phosphorylation. Conclusions and implications: These results indicate that fluvastatin inhibited expression of the CC chemokine MDC induced by IFN-γ in HaCaT cells, by inhibiting NF-κB activation via the p38 MAPK pathway. This blockade of a Th2 chemokine by fluvastatin may suppress the infiltration of Th2 cells into skin lesions and lessen the skin inflammation seen in atopic dermatitis, suggesting a potential therapeutic use of fluvastatin for this condition.

UR - http://www.scopus.com/inward/record.url?scp=70350323989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350323989&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2009.00311.x

DO - 10.1111/j.1476-5381.2009.00311.x

M3 - Article

C2 - 19594754

AN - SCOPUS:70350323989

VL - 157

SP - 1441

EP - 1450

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -